Six boys aged 0.69-1.88 years with stable chronic renal failure /min/1.732~~) and renal osteodystrophy, previously controlled with k-hybroxycholecalciferol, (lo(-OHCC 26-48ng/kg/day), were treated for two consecutive four month periods in random order, with their established dose of W-OHCC or placebo. During treatment with M-OHCC there was a tendency for improvement in Xrays of hand, wrist and h e e associated with a fall in alkaline phoephatase (mean change -116 iu/l), whilst during the placebo period the bone Xrays showed deterioration with most marked changes at the h e e , and the alkaline phosphatase rose (mean change +124 iu/l, t=2.77, p<0.02).
London, England.
Six boys aged 0.69-1.88 years with stable chronic renal failure /min/1.732~~) and renal osteodystrophy, previously controlled with k-hybroxycholecalciferol, (lo(-OHCC 26-48ng/kg/day), were treated for two consecutive four month periods in random order, with their established dose of W-OHCC or placebo. During treatment with M-OHCC there was a tendency for improvement in Xrays of hand, wrist and h e e associated with a fall in alkaline phoephatase (mean change -116 iu/l), whilst during the placebo period the bone Xrays showed deterioration with most marked changes at the h e e , and the alkaline phosphatase rose (mean change +124 iu/l, t=2.77, p<0.02).
Plasma immunoreactive parathormone concentration increased during both periods (mean change +258 ng/l on Id-OHCC, +j9l d l on placebo). Plasma calcium concentration fell during placebo therapy (mean change -0.17 mmol/l), but remained unchanged during the lo(-OHCC period. Renal function was unaffected: estimated GFFI showed a mean change of +2.7% during treatment with a-OHCC and -0.6% with placebo. There were no changes in body fluid composition or linear growth which could be attributed to %-OHCC.
We conclude that Id-OHCC is a moderately effective and safe treatment of renal osteodystrophy in young children with renal failure.
SKELETAL MANIFESTATIONS OF RENAL OSTEODYS-

TROPHY IN CHILDREN
Mehls,O., Gilli,G., Ritz,E., Oppermann,H.C. University Children's Hospital, Heidelberg, F.R.G.
The nature of skeletal lesions in renal osteodystrophy(R0) is still controversial. Our experience is based on sequential X-ray studies of 211 children with chronic renal failure(CRF1with or without haemodialysis (HD) and iliac crest histology of 9 8 children.l.Histo-%:Abnormal bone histology(increased osteoid, endosteal fibrosis, Howship's 1acunae)is encountered even in incipient RF(SCr 2.5 mg/dl)together with an increase o f PTH. HD fails to normalize the bony changes. In terminal RF, growth cartilage mineralization is preserved and osteitis fibrosa is present in the metaphysis(primary and secondary spongiosa). These lesions are distinct from classical rickets. 2.Radioloqll:Cortical lesions(subperiosta1 resorption,periostal neostosis,cortical striation)are more frequent than in adults and obligatorily accompanied by changes in the growth zone: in contrast to distinct histology radiolucent zones are indistinguishable from rickets. 3 important biochemical consequences are observed: a)metaphyseal deformitiesof tubular bones, b) epiphyseal slipping and c) metaphyseal fractures. Advanced RO is always accompanied byretardation of growth and bone maturation. In agreement with the high rate of bone turnover in childrenlesions may appear ra idly and disappear likewise rapidly in response to tEerapy. Five adolescents and three children were treated for 48 weeks with 1-25 OH D3 at the dose of 2 or 3 pg weekly. Biological controls, hand roentgenograms and bone biopsies were performed before and after treatment. Treatment did not modify growth velocity. Radiologic healing of osteodystrophy was observed. Serum calcium significantly increased, while alcaline pho-phatase decreased and iPTlt varied from 7556 2 366 pg/ml to 3657 t 763 pglml (p <0,001, normal 250 +_ 134 pglml). Serum phosphorus significantly decreased from the fourth to the sixteenth week and then progressively increased. Prior to treatment all cases presented with classical histomorphometric signs of hyperparathyroidism. During therapy these patients showed a decrease in the number of osteoclasts per mm2 and trabecular osteoclastic resorption surface (T.O.R.S.). Following treatment, normal trabecular osteoid volume (T.O.V.) and elevated trabecular osteoid surface (T.O.S.) values were observed. Therefore 1-25 OH D3 corrected both biological and histological signs of hyperparathyroidism in only two patients,. However the remaining cases showed regression of these signs.
Life table analyses were applied for statistical evaluation. During the period 1970-1974.5 year graft survival in the LRD group (n=21) was 43% and improved to 65% (n-17) during the subsequent 5 year period. From 1970 From -1974 year survival in the C group (11x21) was 33% and increased to 47% (11-39) between 1975 and 1979 . Ten year graft survival in the LRD group (n=38) is 53% compared with 43% graft survival in the C group (~60). Most grafts that were lost ceased functioning early. Twenty nine percent (11138) of LRD grafts and 35% (21160) of C grafts were lost in the initial 3 months post-transplant. No LRD grafts were lost after 2 years except in one patient who had recurrence of focal segmental glomerulosclerosis 3.5 years post-transplant. Only one C graft was lost after 3 years. Patient survival was 95% (72176). Results of our 10 year experience confirm that renal transplantation is a viable therapeutic modality in children. Our experience suggests if improvement in graft survival is to occur, factors in the perioperative period such as tissue typing, immunosupression, and the role of blood transfusions need further evaluation. 
